Kidney function may affect how new antibiotic combo works

NCT ID NCT05488678

Completed Knowledge-focused Sponsor: Basilea Pharmaceutica Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study tested how a single dose of the antibiotic combination ceftibuten/VNRX-7145 is processed by the body in 32 adults with normal or impaired kidney function, including those on dialysis. Researchers measured drug levels in the blood and monitored safety. The goal was to gather information for future dosing recommendations, not to treat an infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ceftibuten and VNRX-7145 (an experimental antibiotic combination)
What this could lead to: If successful, this could help doctors understand how to dose this antibiotic safely for patients with kidney problems.
What could go wrong: This is a very early, small study (32 people) focused on drug levels and safety, not on treating an infection. It may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PHARMACOKINETICS

Contacts and locations

Locations

Advanced Pharma

Miami, Florida, 33147, United States
Nucleus Network

Saint Paul, Minnesota, 55114, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.